These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling. Zang Y; Guo B; Han Y; Cao S; Zhang C Stat Med; 2019 Jul; 38(15):2883-2896. PubMed ID: 30968435 [TBL] [Abstract][Full Text] [Related]
5. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies. Su L; Chen X; Zhang J; Gao J; Yan F Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917 [TBL] [Abstract][Full Text] [Related]
6. A subgroup cluster-based Bayesian adaptive design for precision medicine. Guo W; Ji Y; Catenacci DVT Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814 [TBL] [Abstract][Full Text] [Related]
7. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect. Shan M; Guo B; Liu H; Li Q; Zang Y Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375 [TBL] [Abstract][Full Text] [Related]
8. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519 [TBL] [Abstract][Full Text] [Related]
9. Subgroup identification for treatment selection in biomarker adaptive design. Lu TP; Chen JJ BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831 [TBL] [Abstract][Full Text] [Related]
10. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. Guo B; Zang Y Stat Methods Med Res; 2022 Jun; 31(6):1104-1119. PubMed ID: 35191780 [TBL] [Abstract][Full Text] [Related]
11. A Bayesian adaptive design with biomarkers for targeted therapies. Eickhoff JC; Kim K; Beach J; Kolesar JM; Gee JR Clin Trials; 2010 Oct; 7(5):546-56. PubMed ID: 20571131 [TBL] [Abstract][Full Text] [Related]
13. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Chu Y; Yuan Y Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621 [TBL] [Abstract][Full Text] [Related]
14. An adaptive biomarker basket design in phase II oncology trials. Liu S; Takeda K; Rong A Pharm Stat; 2023 Jan; 22(1):128-142. PubMed ID: 36163614 [TBL] [Abstract][Full Text] [Related]
15. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation. Morita S; Yamamoto H; Sugitani Y Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639 [TBL] [Abstract][Full Text] [Related]
16. Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations. Wheaton L; Jackson D; Bujkiewicz S Res Synth Methods; 2024 Jul; 15(4):543-560. PubMed ID: 38316618 [TBL] [Abstract][Full Text] [Related]
17. Optimized adaptive enrichment designs. Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436 [TBL] [Abstract][Full Text] [Related]
18. RoBoT: a robust Bayesian hypothesis testing method for basket trials. Zhou T; Ji Y Biostatistics; 2021 Oct; 22(4):897-912. PubMed ID: 32061093 [TBL] [Abstract][Full Text] [Related]
19. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination. Chapple AG; Thall PF Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806 [TBL] [Abstract][Full Text] [Related]
20. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials. Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]